Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Technical Presentation (July 2018)
10 slides from Nemaura Medical's technical presentation, Jul 31, 2018
Slide 1: Better Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Interim Clinical Presentation of Comparative Home-use Study 31st July 2018
Slide 2: A Prospective Single Centre Evaluation of the Accuracy and Safety of the sugarBEAT CGM
A Prospective Single Centre Evaluation of the Accuracy and safety of the sugarBEAT® Non-invasive Continuous Glucose Monitor (CGM) System: An interim Evaluation Dr T Rahman, MBBS, PhD Clinical research Manager, Nemaura Medical Inc., 2
Slide 3: Study Objective
Study Objective A EU based study to determine the safety and accuracy of the sugarBEAT® CGM, to support FDA submission. 3
Slide 4: Study Design
Study Design ❖Prospective single arm, single centre study ❖Accuracy and safety to be assessed on 75 patients over 525 wear days ❖Venous blood samples used as reference for in-clinic portion of study ❖Abbott Freestyle Optimum Neo BGM used as reference for Home Study Portion 4
Slide 5: Study Methods
Study Methods ❖>25 subjects enrolled for screening ❖25 subjects selected after screening in stage 1, of which 12 were Type 1 and 13 Type 2 diabetic ❖No subjects lost due to drop out in stage 1 ❖All 25 subjects completed 2 days home study and 3 days in- clinic study, in stage 1 ❖12 subjects wore devi
Slide 6: Baseline Characteristics
(~")sugarBEATe Baseline 6 Characteristics Variable Age (range and mean) 20 years to 70 years, Mean age 45.2 Gender 12 Male, 13 Female Type 1/Type 2 12 Type 1, 13 Type2 «ys
Slide 7: Accuracy vs Glucose Range
Accuracy vs Glucose Range The performance evaluation included the proportion of the CGM system values that are within ±15 to 40% of relative difference of reference value at glucose levels >80 mg/dL and ±20 mg/dL of absolute difference at glucose level ≤80 mg/dl, ref: http://journals.sagepub.com/doi
Slide 8: Interim Comparative MARD for home-study phase as Primary Accuracy Metric
Interim Comparative MARD for home-study phase as Primary Accuracy Metric *http://www.diabetesincontrol.com/accuracy-comparison-of-the-dexcom-g5-abbott-freestyle-libre-pro-and- senseonics-eversense/ 8
Slide 9: Safety Evaluation
Safety Evaluation Previous studies: >100 Patient days wear time – No major adverse events or skin irritation reported. 525 Patient days wear time – No major adverse events or skin irritation reported. Current study: 125 Patient days to date with no major adverse events or skin irritation reported. 9
Slide 10: Conclusion
Conclusion The interim analysis indicates the home portion of the study shows accuracy levels, measured using overall nominal MARD, as being comparable to independently published data on the three market leading CGM’s. 10